Read speeches, public addresses and congressional testimony by PhRMA CEO and President John Castellani and other pharmaceutical industry leaders. Click on any of the links below to read one of the speeches.
As life science trade associations representing thousands of medical device, biotechnology and pharmaceutical companies, we express our longstanding support for the goals of the Physician Payments Sunshine Act (“the Sunshine Act”), section 6002 of the Affordable Care Act of 2010, which will provide transparency in industry collaboration with teaching hospitals, physicians; and report physician ownership and investment interests.
Good morning. Welcome to what Harry Truman called, “Washington’s second-best address.” I want to thank Bob Hugin and the entire Celgene team for their hard work in organizing this meeting. And thank you, PhRMA Board Members, particularly Ian Read of Pfizer – our incoming chairman. Read more.
Thomas Edison distilled his innovative process down to this: I find out what the world needs, then I proceed to invent it. Read more.
Thank you, Dick (Maas). Also, thank Raju and the other for inviting me to be part of this year’s program. The last time I was here at this meeting I was speaking from the translational medicine perspective as the Executive Dean for Research at the Harvard Medical School but I am excited to be speaking today from the perspective of the biopharmaceutical industry, which is equally committed to healing and meeting the health needs of patients through advancing personalized medicine.
My thanks also to the Partnership to Fight Chronic Disease for inviting me to be here today. Believe me, it is wonderful to leave the gloom and doom of Washington, DC, behind, if only for a few days. More importantly, at PhRMA we’re proud of the fact that we were “present at the creation” of PFCD and we continue to be strong supporters of the work you do. Anyone who takes a close look at the state of the nation’s healthcare understands how important that work is. Read more.
Thank you all for joining me today. I am Bob Hugin, Chairman of PhRMA and Chairman/ CEO of Celgene Corporation – a leading medical innovator whose objective to is to help patients with cancer and immune-related and inflammatory conditions live longer and better quality lives. Read more.
Nearly 140 years ago – not too far from here in Menlo Park – Thomas Edison invented the modern research laboratory. Edison’s imagination, innovativeness, hard-work and persistence helped to usher in the modern age and create the world we share today. That world was very different then. Edison’s work was personal. His laboratory and staff were initially small. He required minimal investment and few resources. Yet he could deliver – quickly translating good ideas and his profound mechanical insight into invention after invention in relatively rapid succession. Read more.
Thank you, Dr. Puckrein for that kind introduction. And my thanks to Representative Donna Christensen and Gary Puckrein for inviting me to speak at your Braintrust/Leadership Summit Awards Dinner. And Dr. Christensen, please know how much everyone here tonight admires you and your long history of public service. I am so honored to share the podium with Dr. Davidson, and to join in celebrating his work to promote and protect the health of all Americans. Read more.
I can't tell you how excited and honored I am to be here this morning. I am truly humbled by the opportunity and responsibility of becoming the Chairman of the Board of PhRMA. When I joined the PhRMA Board six years ago, I could have never imagined being on this stage this morning. I joined the PhRMA Board to give Celgene new insight as to the coming changes in healthcare reform and how they would affect our vision and mission. Read more.
Good afternoon and welcome back. I hope you enjoyed lunch and Dan Pink’s thought-provoking talk. We at PhRMA are thrilled to be in San Diego for this year’s meeting. I want to thank John Lechleiter and the Eli Lilly team for their work and contributions to this meeting. I also want to thank all the PhRMA Board Members and especially our incoming chairman Bob Hugin of Celgene who inherits the challenge of overseeing next year’s meeting. Read more.
Thank you for that kind introduction. I’m here to talk about the future. But first allow me to address some of the criticism of the biopharmaceutical research industry I’ve heard today. This industry is men and women dedicated to improving the health of everyone. Finding solutions for patients is what gets us up in the morning. It’s why we’ve made extraordinary progress fighting disease. It’s why patients rightly place their hopes in us. Any dialog that helps us advance this cause is welcome. Read more.
Thank you, Victoria and good morning. I want to thank the National Journal and Victoria for all that they have done to make this policy summit possible. There is a scientific proposition developed in-part by the American meteorologist and mathematician Edward Lorenz called chaos theory. It includes something called “the Butterfly Effect.” In its simplest form, everything in the greater ecosystem is inter-related and interconnected. Read more.
Thank you, Keith for that kind introduction. And my thanks to all of you here for joining me this morning. Let me begin by saying I am not now, nor have I ever been, nor will I ever be a candidate for public office. In other words, this will be one of the few press events before November 6 that does not feature someone looking for votes. However, though I’m not on any ballot, I am going to be talking about three of the biggest issues now being discussed by Governor Romney and President Obama. Read more.
In our industry today, everyone uses familiar words to describe what we do: Innovation, progress, technology, value, science, partnership, solutions, jobs and so many more. But to resonate, these words must do more than just describe – they must tell our story. One way we are bringing this narrative to life is through video libraries at PhRMA’s website and Facebook page, containing some of the amazing stories to which we in the biopharmaceutical research industry must always return. They include explanations of how medicines are developed and interviews with researchers talking about the impact and promise of their exciting work. But most importantly there are patient stories. The stories of the men, women and children whose lives are better and whose hope for the future is strong in part because of the medicines developed by PhRMA member companies. Read more.
"Thank you, John, for that kind introduction. And thanks also to the National Italian American Foundation for inviting me to take part in this Series of Distinguished Lectures. To be asked to take part in an event that has featured so many Washington men and women whom I admire… It’s a true honor. And it is a pleasure to be speaking to a room full of people whose names also end in a vowel." Read more.